A new generation of supplements has shed the strip-mall vitamin aesthetic for sleek branding, podcast endorsements, and language borrowed from longevity research. NAD+ precursors, peptide bioregulators, nootropic stacks, methylene blue, sirtuin activators, exogenous ketones — the lineup rotates faster than the evidence does. Influencer protocols, paywalled newsletters, and conference circuits create the impression that an enlightened minority has cracked something the medical establishment is too slow to acknowledge. The actual trial record is much thinner than the marketing implies.
The packaging is new. The pattern is old.
What gets sold versus what gets tested
Most biohacking supplements are sold based on mechanism — a plausible biochemical pathway demonstrated in vitro or in mice — rather than on clinical outcomes in humans. Resveratrol activates sirtuins in yeast and improves health in some mouse models; the human trials have been disappointing and inconsistent. NAD+ boosters like NR and NMN raise blood NAD+ levels, but the human evidence for downstream benefits in healthy adults remains preliminary, with small trials and modest effects. Nootropic stacks combining racetams, choline donors, and adaptogens rarely have head-to-head trials against caffeine, which is cheap, well-characterized, and often comparably effective for the alertness outcomes consumers actually care about. Methylene blue is having a moment despite a sparse human evidence base outside specific clinical applications. The pattern: pathway plausibility plus animal data plus a few small human trials gets translated into confident consumer claims.
The information ecosystem is the product
Biohacking media is structured to convert curiosity into purchases. Long-form podcasts feature founders of supplement companies discussing their own products, often without clear disclosures. Substack newsletters bundle paid sponsorships into recommendation posts. Conferences sell speaking slots that double as product launches. The result is an information environment where the same dozen molecules cycle through with increasing confidence as more credentialed-sounding people repeat the claims. Citation chains often loop back to a small number of original studies that are themselves preliminary. Replication failures, when they happen, get less coverage than initial findings. None of this is unique to biohacking — it’s the standard pattern of any wellness category — but the science-adjacent framing makes it easier to mistake for evidence-based practice.
What modest evidence actually supports
A small set of interventions has reasonable support for healthspan-related outcomes in humans. Vitamin D supplementation when deficient. Omega-3s in some cardiovascular contexts, with shrinking effect sizes. Creatine for muscle and cognitive performance with reasonably solid trial backing. Caffeine for alertness. Resistance training for nearly every aging-related outcome. Sleep regularity. Mediterranean-pattern eating. None of these are exotic, none require subscription protocols, and none are exciting enough to anchor a brand. The unsexy interventions outperform the branded stacks on the metric that matters — durable evidence in humans — by a wide margin.
The takeaway
If a supplement is being sold mainly through podcasts and influencer protocols rather than discussed in cardiology, neurology, or geriatrics journals, that’s a signal. The cheap, boring interventions have the receipts. The branded stacks are mostly selling identity to people who can afford to experiment, which is fine as a hobby and expensive as a health strategy.
Leave a Reply